{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-060391","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.813620+00:00","generated_at":"2026-05-18T10:13:23.405452+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025","bullets":["Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).","Purchased $1.42M Evofem convertible note and warrant for $925K; convertible at $0.0154/share, warrant exercisable for 5 years.","Evofem reported ~$20M revenue in 2024; CEO says pending acquisition target close by end of September 2025, subject to shareholder approval.","Pearsanta near commercialization (end 2025/Q1 2026) for prostate cancer and endometriosis tests using mitochondrial DNA.","Adimune autoimmune therapeutic platform still early stage; described as 'sleeping giant'; retraining immune system approach."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-060391","json":"https://secwatch.observer/filing/0001213900-25-060391.json","markdown":"https://secwatch.observer/filing/0001213900-25-060391.md","text":"https://secwatch.observer/filing/0001213900-25-060391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/0001213900-25-060391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/ea0247298-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:13:23.405452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80a39876a3e96f2f9048990d70c129d530ef5cc2","claim":"Aditxt, Inc. incurred senior notes of $1,000,000 aggregate original principal amount with accredited investors at 10% per annum maturing September 30, 2025.","evidence_excerpt":"On June 26, 2025, Aditxt, Inc. (the “ Company ”) issued and sold senior notes (each, a “ Note ”) to accredited investors in the aggregate original principal amount of $1,000,000 for a purchase price of $800,000, reflecting an aggregate original issue discount of $200,000. The Notes bear interest at a rate of 10% per annum and have a maturity date of September 30, 2025 (the “ Maturity Date ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/0001213900-25-060391-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$1,000,000 aggregate original principal amount"},{"label":"Counterparty","value":"accredited investors"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"September 30, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}